Company (Symbol) |
Offer Date |
Number Shares/Units (M)* |
Price Per Share/Unit ($) |
Gross ($M)* |
Net ($M) |
Shares Out (M) | Post Offering Market Cap ($M)@ | Lead UnderWriter** |
Other UnderWriters |
Powderject Pharmaceuticals plc1 (LSE:PJP; UK)*** |
2/1 |
8.0S | $11.06 |
$88.8 |
$85.8 |
72.4 | $800 |
RF |
|
Abgenix Inc. (ABGX) | 3/4 | 3.2S |
$15.00 | $48.5 | $48.1 |
14.8 | $222 | BRS | LB, PGE |
ChiRex Inc.2 (CHRX) |
3/19 |
2.9S |
$19.00 | $54.6 |
$51.1 | 12.3 | $234 | CSFBC |
DRW, HQ, LM |
QLT Phototherapeutics Inc. (QLTI) |
3/30 |
3.16S |
$43.63 | $138.0 |
$131.1 |
27.3 | $1,191 |
CIBC | BTAB, INGB, NB, WDR |
Cerus Corp. (CERS) | 3/31 | 2.2S | $21.00 | $46.2 | $43.9 | 11.4 | $239 | MSC | BTAB, SGC |
AltaRex Corp. (TSE:AXO)*** |
5/7 | 39.1S | $0.34 |
$13.3 |
$112.1 |
55.1 | $19 | FMSL |
HSBC |
Synsorb Biotech Inc. (SYBB; TSE: SYB)*** |
5/13 | 10.1S |
$1.17 |
$11.9 | $11.3 | 30 | $35.1 | TDS |
HSBC, LOM, CCC |
Trimeris Inc. (TRMS) | 5/27 | 2.9S |
$11.75 |
$33.8 |
$31.4 |
13.6 |
$160 |
INGB | BRS, SGC |
Alliance Pharmaceutical Corp. (ALLP) |
6/11 |
9.5 |
$2.45 |
$23.3 |
$22.1 |
33.2 |
$81 | CR (placement agent) | |
Ribozyme Pharmaceuticals Inc. (RZYM) |
7/7 |
1.8S |
$3.50 |
$6.3 |
$5.8 |
11 | 39 | HQ (placement agent) | |
Angiotech Pharmaceuticals Inc. (TSE:ANP)*** |
7/9 |
1.4S |
$7.8 |
$10.9 |
$10.4 |
LBG | LOM | ||
Alizyme plc3 (LSE:AZM)*** |
7/21 |
7.0U |
$1.19 |
$8.4 |
$7.9 |
49 | $58.3 |
N/A |
January - July 1999 FOLLOW-ON TOTAL: $484.0
NOTES:
* Number of shares (or units) sold in the offering includes those sold to satisfy overallotment options, in full or in part, when disclosed. Likewise, gross proceeds include revenues for the sale of shares (or units) to satisfy overallotment options, in full or in part, where applicable. | |||||||||
** See Underwriters' Key on Page 6 | |||||||||
***Converted to U.S. dollars based on exchange rate at the time of the offering. | |||||||||
@ Market capitalization calculated is based on offering price. | |||||||||
LSE=London Stock Exchange; TSE=Toronto Stock Exchange | |||||||||
1 PowderJect Pharmaceuticals plc sold 8.03M common shares on the London Stock Exchange (LSE) in a placing and open offer on a 1-for-8 basis. Prices have been converted at an exchange rate of £0.606/US$1. | |||||||||
2 ChiRex Inc. filed a shelf registration in 1998, which became effective on 12/28/98, covering the future sale of up to $100M in debt securities, preferred stock, depositary shares, warrants and common stock. The shares were offered as part of that shelf registration. | |||||||||
3 Alizyme plc's offered units, each consisting of two ordinary shares and one warrant, exercisable at 40p |